Skip to content

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03136198
Acronym
BLUSHED-AHF
Enrollment
130
Registered
2017-05-02
Start date
2017-07-10
Completion date
2019-06-20
Last updated
2024-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure

Keywords

Heart Failure, Acute Heart Failure, Pulmonary Edema, Lung ultrasound, Extra vascular lung water, B-lines

Brief summary

Nearly 80% of acute heart failure (AHF) patients admitted to the hospital are initially treated in the emergency department (ED). Once admitted, within 30 days post-discharge, 27% of patients are re-hospitalized or die. Attempts to improve outcomes with novel therapies have all failed. The evidence for existing AHF therapies are poor: No currently used AHF treatment is known to improve outcomes. ED treatment is largely the same today as 40 years ago. Congestion, such as difficulty breathing, weight gain, and leg swelling, is the primary reason why patients present to the hospital for AHF. Treating congestion is the cornerstone of AHF management. Yet half of all AHF patients leave the hospital inadequately decongested. The investigators propose a novel approach to aggressively decongest patients in the ED setting: lung ultrasound guided, protocol driven, AHF management. LUS B-lines are a measure of extra-vascular lung water (EVLW). In the setting of AHF, LUS B-lines are a measure of congestion. This simple, easily learned technique has excellent reliability and reproducibility. The investigators hypothesize that a strategy-of-care will outperform usual care. At the present time, usual care is largely empirical. This study will improve the evidence base for ED AHF management. This proposed pilot study, if successful, will lead to an outcome trial examining whether an ED AHF strategy-of-care increases days alive and out of the hospital for patients.

Detailed description

The primary goal of the BLUSHED AHF pilot trial is to determine whether an early lung ultrasound (LUS) guided, protocol-driven ED AHF strategy-of-care leads to more rapid and sustained resolution of congestion, as measured by LUS B-lines. If the investigators are able to demonstrate this necessary and sufficient information - targeted strategy-of-care is more effective than usual care - they will apply for a follow on study to achieve the following aim. Aim 1: To demonstrate the effectiveness of a targeted decongestion strategy - LUS guided, protocol-driven ED AHF management - will result in improved 30-day outcomes vs. usual care. This aim will be tested using a randomized, controlled, unblinded, pragmatic, multi-center, simple trial design. The pilot trial may determine that ED management alone is insufficient to impact the outcome. Thus, the investigators may need to modify their subsequent trial design to include targeted therapy throughout hospitalization. However, the pilot study will demonstrate whether targeted therapy effectively reduces B-lines. PUBLIC HEALTH IMPACT Over one million hospitalizations for AHF occur every year in the US. Within 30 days after hospitalization, over 25% of AHF patients will be dead or re-hospitalized.4 Up to 67% of patients will be re-hospitalized and 36% will be dead by one year. For patients aged 65 years and older, AHF is the most common and most expensive reason for hospitalization. Despite major reductions in morbidity and mortality for chronic HF, considerably less progress has been seen in AHF. Congestion is the primary reason why AHF patients present to the ED seeking medical care. Congestion is manifest by signs and symptoms of heart failure (HF); dyspnea, orthopnea, edema, and weight gain. Yet, how to best assess, grade, and manage congestion is not well established. Freedom from congestion is associated with improved outcomes; Yet many patients leave the hospital inadequately decongested. The absence of robust, reliable methods to assess congestion is a primary reason why it is not well-assessed. A recent consensus statement published in 2010 highlights this fact: …no method to assess congestion…has been validated. The investigators would argue many ED AHF patients are poorly assessed prior to treatment. In addition, they are poorly re-assessed prior to hospitalization to gauge the success or failure of initial management. While physical exam is currently the cornerstone of congestion assessment, it lacks sensitivity and inter-rater reliability. The investigators challenge the current paradigm of relying on insensitive methods of congestion to guide therapy. Furthermore, they argue the lack of a robust evidence base for ED management of congestion contributes to poor outcomes.

Interventions

OTHERLUS-guided strategy-of-care

For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first. Treatment protocol: 1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive. 2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV) 3. Reassessment every 2 hours

OTHERUsual Care

Patients will receive usual AHF care

DRUGIntravenous Loop Diuretic

IV loop diuretic

IV, topical, or SL Vasodilator

Face, mouth, or nasal mask applied to provide positive pressure ventilation

Sponsors

Inova Fairfax Hospital
CollaboratorOTHER
Vanderbilt University
CollaboratorOTHER
Case Western Reserve University
CollaboratorOTHER
Wayne State University
CollaboratorOTHER
Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Investigator)

Masking description

A central, independent, Core Lab will review all images.

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 21 years * Presents with shortness of breath at rest or with minimal exertion * Clinical diagnosis of AHF and presence of \> 15 total bilateral B-lines distributed in at least 4 zones on initial LUS * Hx of chronic HF and any one of the following: * Chest radiograph consistent with AHF * Jugular venous distension * Pulmonary rales on auscultation * Lower extremity edema

Exclusion criteria

* Chronic renal dysfunction, including end-stage renal disease (ESRD) or estimated glomerular filtration rate (eGFR) \< 45ml//min/1.73m2. * Shock of any kind. Any requirement for vasopressors or inotropes. * Systolic blood pressure (SBP) \< 100 or \>175 mmHg * Need for immediate intubation * Acute Coronary Syndrome- Presentation consistent with myocardial ischemia AND either new ST-segment elevation/depression * Fever \>101.5 ºF or chest radiograph or clinical picture of pneumonia * End stage HF: transplant list, ventricular assist device * Anemia requiring transfusion * Known interstitial lung disease * Suspected acute lung injury or acute respiratory distress syndrome (ARDS) * Pregnant or recently pregnant within the last 6 months

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF ManagementDuring the ED phase of management, usually no more than 6 hoursB-lines ≤ 15 at the conclusion of ED AHF management or maximum of 6 hours after enrollment, whichever comes first.

Other

MeasureTime frameDescription
Association of B-lines at Discharge and 30-day / 90-day OutcomesUp through 90 days, with specific reporting of events through 30 and 90 days
Change in Biomarkers From Presentation to Pre-dischargeFrom admission to pre-discharge from the hospital, on average 5 to 7 days.
Time to Reach B-lines <15Throughout hospitalization, on average 5-7 days
B Lines < 15 at 24 Hours and at DischargeThrough the first 24 hours and then prior to discharge, on average 5-7 days after admission
Composite of 30-day and 90-day All-cause Mortality, Cardiovascular (CV) Re-hospitalizations, and CV Emergency Department (ED) Revisits.Up through 90 days, with specific reporting of events through 30 and 90 daysCV endpoints are defined according to the 2014 American College of Cardiology/American Heart Association (ACC/AHA) Key Data Elements and Definitions for Cardiovascular Endpoint Events.
Total Days Alive and Out Of Hospital (DAOOH)Up through 90 days, with specific reporting of events through 30 and 90 daysTotal days alive and out of hospital through 30 and 90 days post-discharge
Number of Participants With Physical Exam Findings of Heart Failure When Discharge is Compared to BaselineFrom admission throughout hospitalization, usually 5-7 days.Physical exam includes body weight, peripheral edema, jugular venous distention, pulmonary and cardiac auscultation
Count of Pharmacologic Therapies the Patient Received in the EDFrom admission throughout hospitalization, usually 5-7 days.This is a description of which pharmacologic therapies the patient has received.
Count of Pharmacologic and Device Therapies the Patient Received During HospitalizationFrom admission throughout hospitalization, usually 5-7 days.This is a description of which pharmacologic and device therapies the patient has received.
Comparison of LUS Interpretation Within and Between Trained Investigators as Well as the Core LabFrom admission throughout hospitalization, usually 5-7 days.Calculation of intra and inter-agreement between investigators and also the Core Lab to determine the reproducibility of LUS
Association of Baseline, Discharge, and Change With 30 and 90 Day OutcomesUp through 90 days, with specific reporting of events through 30 and 90 days
All Cause Readmissions, All Cause ED Re-visitsUp through 90 days, with specific reporting of events through 30 and 90 days30- day and 90-day

Countries

United States

Participant flow

Participants by arm

ArmCount
LUS-guided Strategy-of-care
Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice. LUS-guided strategy-of-care: For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first. Treatment protocol: 1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive. 2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV) 3. Reassessment every 2 hours Intravenous Loop Diuretic: IV loop diuretic Vasodilator: IV, topical, or SL Vasodilator Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation
66
Usual Care
Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care. Usual Care: Patients will receive usual AHF care Intravenous Loop Diuretic: IV loop diuretic Vasodilator: IV, topical, or SL Vasodilator Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation
64
Total130

Baseline characteristics

CharacteristicLUS-guided Strategy-of-careTotalUsual Care
Age, Continuous63.8 years
STANDARD_DEVIATION 15.9
65.0 years
STANDARD_DEVIATION 14.2
66.2 years
STANDARD_DEVIATION 12.2
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants3 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
63 Participants124 Participants61 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants3 Participants2 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
35 Participants69 Participants34 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants1 Participants
Race (NIH/OMB)
White
30 Participants59 Participants29 Participants
Region of Enrollment
United States
66 participants130 participants64 participants
Sex: Female, Male
Female
19 Participants37 Participants18 Participants
Sex: Female, Male
Male
47 Participants93 Participants46 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 660 / 64
other
Total, other adverse events
8 / 6615 / 64
serious
Total, serious adverse events
2 / 662 / 64

Outcome results

Primary

Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management

B-lines ≤ 15 at the conclusion of ED AHF management or maximum of 6 hours after enrollment, whichever comes first.

Time frame: During the ED phase of management, usually no more than 6 hours

Population: Out of the 130 participants a total of 8 (5 in the LUS-guided strategy of care arm and 3 in the Usual care arm) had a recorded ED discharge time which was prior to the first LUS, leaving 61 participants in each arm to be analyzed for the primary outcome.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LUS-guided Strategy-of-careNumber of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management7 Participants
Usual CareNumber of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management10 Participants
Other Pre-specified

All Cause Readmissions, All Cause ED Re-visits

30- day and 90-day

Time frame: Up through 90 days, with specific reporting of events through 30 and 90 days

Other Pre-specified

Association of Baseline, Discharge, and Change With 30 and 90 Day Outcomes

Time frame: Up through 90 days, with specific reporting of events through 30 and 90 days

Other Pre-specified

Association of B-lines at Discharge and 30-day / 90-day Outcomes

Time frame: Up through 90 days, with specific reporting of events through 30 and 90 days

Other Pre-specified

B Lines < 15 at 24 Hours and at Discharge

Time frame: Through the first 24 hours and then prior to discharge, on average 5-7 days after admission

Other Pre-specified

Change in Biomarkers From Presentation to Pre-discharge

Time frame: From admission to pre-discharge from the hospital, on average 5 to 7 days.

Other Pre-specified

Comparison of LUS Interpretation Within and Between Trained Investigators as Well as the Core Lab

Calculation of intra and inter-agreement between investigators and also the Core Lab to determine the reproducibility of LUS

Time frame: From admission throughout hospitalization, usually 5-7 days.

Other Pre-specified

Composite of 30-day and 90-day All-cause Mortality, Cardiovascular (CV) Re-hospitalizations, and CV Emergency Department (ED) Revisits.

CV endpoints are defined according to the 2014 American College of Cardiology/American Heart Association (ACC/AHA) Key Data Elements and Definitions for Cardiovascular Endpoint Events.

Time frame: Up through 90 days, with specific reporting of events through 30 and 90 days

Other Pre-specified

Count of Pharmacologic and Device Therapies the Patient Received During Hospitalization

This is a description of which pharmacologic and device therapies the patient has received.

Time frame: From admission throughout hospitalization, usually 5-7 days.

Other Pre-specified

Count of Pharmacologic Therapies the Patient Received in the ED

This is a description of which pharmacologic therapies the patient has received.

Time frame: From admission throughout hospitalization, usually 5-7 days.

Other Pre-specified

Number of Participants With Physical Exam Findings of Heart Failure When Discharge is Compared to Baseline

Physical exam includes body weight, peripheral edema, jugular venous distention, pulmonary and cardiac auscultation

Time frame: From admission throughout hospitalization, usually 5-7 days.

Other Pre-specified

Time to Reach B-lines <15

Time frame: Throughout hospitalization, on average 5-7 days

Other Pre-specified

Total Days Alive and Out Of Hospital (DAOOH)

Total days alive and out of hospital through 30 and 90 days post-discharge

Time frame: Up through 90 days, with specific reporting of events through 30 and 90 days

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026